Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Start Date
4/22/2026
Completion Date
3/2/2029
Summary
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Eligibility Criteria
Age Range: 18 years to 85 years
Interventions
Aritinercept
Placebo
Conditions
Locations
Aurinia Investigational Site
Pasadena, California 91106
United States
Aurinia Investigational Site
Altamonte Springs, Florida 32714
United States
Aurinia Investigational Site
Boca Raton, Florida 33487
United States
Aurinia Investigational Site
Homestead, Florida 33033
United States
Aurinia Investigational Site
Miami, Florida 33155
United States
Aurinia Investigational Site
Miami, Florida 33173
United States
Aurinia Investigational Site
Chicago, Illinois 60616
United States
Aurinia Investigational Site
O'Fallon, Illinois 62269
United States
Aurinia Investigational Site
Dearborn, Michigan 48126
United States
Aurinia Investigational Site
Flint, Michigan 48507
United States
Aurinia Investigational Site
Houston, Texas 77027
United States